Fla. AG goes after Bayer again - Boston Business Journal:

olimstgon.blogspot.com
On Monday, Bill McCollum said he has filed a stipulater supplemental judgment against the drug maker that adds new requirements to a 2007 judgmentt relating to its advertisement forcertain drugs. That agreemeng related to alleged deceptive advertisingof products, including nondisclosure of safety riska associated with its marketing of , a cholesterol-lowerintg drug. Monday’s judgment resolves allegationsthat Bayer’e 2008 marketing campaign for the Yaz oral contraceptive violated the 2007 As part of the the drug company must submit its proposed televisionm ads for Yaz to the FDA for approval before Bayer also must also comply with all regulatory comments the FDA makesz regarding the advertising and, in all print ads, must clearlh and conspicuously disclose exactly which medical conditions and symptoms the drug is FDA-approved for when referrinyg to treatment.
“In an earlieer warning letter to Bayer, the FDA addresseds two misleading direct-to-consumer television advertisementds for Yaz in which Bayer claimed Yaz coulrd treat the symptoms ofpremenstrual syndrome, although Yaz does not have FDA approval for that The letter also warnexd Bayer about promoting the drug as treatment for typea of acne it is not approved to and for exaggerating the effects Yaz had on In addition to changes in its advertising Bayer also must conduct a $20 million corrective advertisin g program The modification of the settlemengt is pending approval in Browarde County Circuit Court.